I don't think new investors will care. It could take years to settle this and the issue of whether RP was fired for cause or of is non really that important in the scheme of leronlimab. I have seen another otc company uplist with bigger lawsuits (40% of market cap lawsuit vs say 1% here), finding investors for the uplist etc, even with that lawsuit and apparently not a big deal for nasdaq . I suspect after we get the company's response, this will be talked about less and less, until it is rarely mentioned, as I have seen before.

Now if this was a lawsuit over leronlimab, it would be a big deal... this, not so much.